Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Published Online: 2022-07-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alketa Hamzaj•Amishi Y Shah•Andrea B Apolo•Bernard Escudier•Burcin Simsek•Camillo Porta•Christian Scheffold•Christopher M Hocking•Cristina Suárez•Elizabeth R Kessler•Howard Gurney•Jens Bedke•Joshua Zhang•Maria T Bourlon•Mauricio Burotto•Robert J Motzer•Thomas Powles•Toni K Choueiri•Yoshihiko Tomita
